3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Active not recruiting
2
Withdrawn
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Early Stage Triple Negative ER Low Breast Cancer
1
Interventions
pembrolizumab
20
Magnetic Resonance Spectroscopy
13
Specimen Handling
12
Cyclophosphamide
11
fludarabine
10
Radiotherapy
9
Biopsy
9
atezolizumab
7
Nivolumab
7
Radiation
6
Gemcitabine
5
fludarabine phosphate
4
aldesleukin
4
Prednisone
4
Etoposide
4
Cytarabine
4
Cisplatin
4
Carboplatin
4
Blood Specimen Collection
4
ALT-803
4
lenvatinib
3
avelumab
3
X-Rays
3
Vincristine
3
Surveys and Questionnaires
3
Rituximab
3
Phantoms, Imaging
3
Paclitaxel
3
Oxaliplatin
3
Lenalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Interleukin 1 Receptor Antagonist Protein
×
1 year
×
Clear all
NCT06710197
2026-03-05
OZM-034
University Health Network, Toronto
Phase 2
Withdrawn